Clinical Trials Directory

Trials / Unknown

UnknownNCT05245890

Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals

Assocaiton Between Uric Acid Trajecteries and Remission of Non-alcoholic Fatty Liver Disease (NAFLD) in NAFLD Individuals

Status
Unknown
Phase
Study type
Observational
Enrollment
2,000 (estimated)
Sponsor
Ningbo No. 1 Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers

Summary

Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders. A growing body of evidence, comprising a great deal of cross-sectional studies and several prospective ones, also indicates that hyperuricemia is associated with increased prevalence, incidence, and disease severity of non-alcoholic fatty liver disease (NAFLD). Capitalizing on a cohort study in China, the investigators are aimed to assess the associations of SUA trajecteries with remission of NAFLD in NAFLD individuals and examined whether the association differs across subpopulations.

Detailed description

A cohort study was conducted to evaluate the relationship between the SUA trajecteries and remission of NAFLD. The study enrolled employees who were attending their annual health examination. Furrhermore, the investigators are aimed to explore whether the association differs across subpopulations.

Conditions

Timeline

Start date
2022-03-01
Primary completion
2023-03-01
Completion
2024-03-01
First posted
2022-02-18
Last updated
2022-02-18

Source: ClinicalTrials.gov record NCT05245890. Inclusion in this directory is not an endorsement.

Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals (NCT05245890) · Clinical Trials Directory